APTEVO THERAPEUTICS INC (APVO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.27-7.30%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · APVO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -84.8% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 95.2% |
Growth built into the price is above our model estimate.
The price assumes 180.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
APVO — debt issuance
Dated 2026-10-30
Other Events. Filing of Prospectus Supplement On October 30, 2026, Aptevo Therapeutics Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC’) a prospectus supplement (the “Prospectus Supplement” and collectively with the Prior Prospectus (as defined below), the “Prospectus”) under the Company’s effective registration statement on Form S-3 (the “Registration Statement”) (File No. 333-284969), relating to the offer and sale of the Company’s shares of common stock, pa…
Why it matters: Aptevo reported $9.8 million in cash at the end of Q2 and no revenue. The report can show whether cash supports its planned work.
Worry ifThe November 5 report shows cash below $9.8 million and no new named funding for APVO451 or RAINIER.
Less concerning ifThe November 5 report shows cash at or above $9.8 million, or names new funding for APVO451 or RAINIER.
Why it matters: This trial step guides the next test of mipletamig in frontline AML. A delay would push back the planned FDA talk and Phase 2 start.
Supportive ifAptevo says RAINIER dose optimization will finish by December 31, 2026. It plans an FDA meeting and a Phase 2 start in the first half of 2027.
Worry ifAptevo reports the dose work is not complete by December 31, 2026, or moves the FDA talk or Phase 2 start beyond the first half of 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$219 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $956 loss on $10,000 · 9.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,548 loss on $10,000 · 95.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.